EC Number | Application | Comment | Organism |
---|---|---|---|
3.13.2.1 | medicine | antiviral drug design | Bos taurus |
3.13.2.1 | medicine | antineoplastic drug design | Bos taurus |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.13.2.1 | 2'-deoxyadenosine | - |
Bos taurus | |
3.13.2.1 | 2-chloroadenosine | - |
Bos taurus | |
3.13.2.1 | 3-deaza-(+/-)-aristeromycin | - |
Bos taurus | |
3.13.2.1 | 3-deazaadenosine | - |
Bos taurus | |
3.13.2.1 | Inosine | - |
Bos taurus | |
3.13.2.1 | nebularine | - |
Bos taurus | |
3.13.2.1 | tubercidin | - |
Bos taurus |
EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
3.13.2.1 | 0.008 | - |
adenosine | - |
Bos taurus | |
3.13.2.1 | 0.042 | - |
S-adenosyl-L-homocysteine | - |
Bos taurus |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.13.2.1 | S-adenosyl-L-homocysteine + H2O | Bos taurus | - |
adenosine + L-homocysteine | - |
r |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.13.2.1 | Bos taurus | - |
- |
- |
EC Number | Purification (Comment) | Organism |
---|---|---|
3.13.2.1 | to homogeneity | Bos taurus |
EC Number | Reaction | Comment | Organism | Reaction ID |
---|---|---|---|---|
3.13.2.1 | S-adenosyl-L-homocysteine + H2O = L-homocysteine + adenosine | reaction equilibrium is in vitro strongly in direction of synthesis of S-adenosyl-L-homocysteine | Bos taurus |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.13.2.1 | pancreas | - |
Bos taurus | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.13.2.1 | DL-homocysteine + adenosine | - |
Bos taurus | S-adenosyl-DL-homocysteine | - |
r | |
3.13.2.1 | S-adenosyl-L-homocysteine + H2O | - |
Bos taurus | adenosine + L-homocysteine | - |
r |